iBio (STU:0JV0) Beginning Cash Position: €41.58 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0JV0 iBio Inc STU:0JV0
27 GF Score
Price €1.10
GF Value €0.04
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is iBio Beginning Cash Position?

iBio STU:0JV0 -0.09% 27 Beginning Cash Position is €41.58 Mil as of Jun. 2026. GuruFocus rates STU:0JV0 with a GF Score™ of 27/100 and a GF Value™ of €0.04 (Significantly Overvalued). The stock has 3 warning signs investors should review.

iBio's Beginning Cash Position for the quarter that ended in Jun. 2026 was €41.58 Mil.

iBio's quarterly Beginning Cash Position increased from Dec. 2025 (€23.86 Mil) to Mar. 2026 (€25.22 Mil) and increased from Mar. 2026 (€25.22 Mil) to Jun. 2026 (€41.58 Mil).

iBio's annual Beginning Cash Position increased from Jun. 2024 (€6.93 Mil) to Jun. 2025 (€12.49 Mil) but then declined from Jun. 2025 (€12.49 Mil) to Jun. 2026 (€8.32 Mil).

iBio Beginning Cash Position Related Terms

iBio Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for iBio's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iBio Beginning Cash Position Chart

iBio Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.96 26.89 6.93 12.49 8.32

iBio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.50 7.20 23.86 25.22 41.58
STU:0JV0
27GF Score
iBio Inc STU:0JV0
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iBio Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €41.58 Mil mean?
iBio (STU:0JV0) has a Beginning Cash Position of €41.58 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on iBio and its competitors.
Is iBio's Beginning Cash Position too high?
iBio's current Beginning Cash Position is €41.58 Mil. Overall, iBio has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iBio's Beginning Cash Position compare to BSEM and CSBR?
iBio's Beginning Cash Position of €41.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on iBio and its competitors. iBio's current Beginning Cash Position is €41.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iBio stock overvalued right now?
Based on GuruFocus' analysis, iBio (STU:0JV0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €1.10 — trading 2640% above its estimated fair value. The current Beginning Cash Position is €41.58 Mil. iBio's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For iBio (STU:0JV0), the current Beginning Cash Position is €41.58 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iBio (STU:0JV0) Overvalued in 2026?

Based on GuruFocus' analysis, iBio stock appears to be overvalued. The current stock price of €1.10 is trading 2640% above its estimated GF Value™ of €0.04. GuruFocus considers iBio to be Significantly Overvalued.

Key valuation signals for STU:0JV0:

  • Beginning Cash Position: €41.58 Mil
  • GF Value™: €0.04 vs. price of €1.10 (2640% above fair value)
  • GF Score™: 27/100 with 3 warning signs

No single metric tells the full story. See the STU:0JV0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iBio Business Description

Other Exchanges IBIO:USA0JV0:Germany
Address 11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc. is a clinical-stage biotechnology company based in the United States that uses artificial intelligence and machine learning to discover and develop precision antibodies for difficult-to-drug targets. Its pipeline focuses on obesity, cardiometabolic, and cardiopulmonary diseases, and includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, GDF11, and Activin A; IBIO-600; an amylin antibody; and an additional undisclosed target, at various stages of preclinical and clinical development. The company operates as a single reportable segment. As a clinical-stage business, iBio does not yet generate product revenue; it funds research and development primarily through equity financings, collaborations, and licensing arrangements, and it depends on regulatory approvals and partnership or out-licensing deals to advance and commercialize its antibody candidates.
27GF Score

Get the complete analysis for STU:0JV0

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.10
Price
€0.04
GF Value